These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27485059)

  • 1. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.
    Petrushnko W; Gundara JS; De Reuver PR; O'Grady G; Samra JS; Mittal A
    HPB (Oxford); 2016 Aug; 18(8):652-63. PubMed ID: 27485059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
    Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
    J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
    Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric- and intestinal-type marker expression in invasive ductal adenocarcinoma of the pancreas.
    Takano Y; Ohike N; Tajiri T; Asonuma K; Harada K; Takahashi H; Morohoshi T
    Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):424-8. PubMed ID: 22893471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer metastatic to a limited number of lymph nodes has no impact on outcome.
    Baldwin S; Kukar M; Gabriel E; Attwood K; Wilkinson N; Hochwald SN; Kuvshinoff B
    HPB (Oxford); 2016 Jun; 18(6):523-8. PubMed ID: 27317957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease.
    Williams JL; Nguyen AH; Rochefort M; Muthusamy VR; Wainberg ZA; Dawson DW; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
    J Surg Oncol; 2015 Sep; 112(4):396-402. PubMed ID: 26303811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.
    Agalianos C; Gouvas N; Papaparaskeva K; Dervenis C
    HPB (Oxford); 2016 Aug; 18(8):633-41. PubMed ID: 27485057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
    Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well differentiation and intact Smad4 expression are specific features of groove pancreatic ductal adenocarcinomas.
    Izumi S; Nakamura S; Mano S; Akaki S
    Pancreas; 2015 Apr; 44(3):394-400. PubMed ID: 25426619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.
    Sopha SC; Gopal P; Merchant NB; Revetta FL; Gold DV; Washington K; Shi C
    Int J Clin Exp Pathol; 2013; 6(11):2476-86. PubMed ID: 24228110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
    Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
    Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.